中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

128 records (took 0.031 seconds)

    USE OF YSCF, TRUNCATED YSCF AND YSCF HOMOLOGS AS ADJUVANTS
    3.
    发明申请
    USE OF YSCF, TRUNCATED YSCF AND YSCF HOMOLOGS AS ADJUVANTS 审中-公开
    YSCF，截短YSCF和YSCF HOMOLOGS作为ADJUVANTS的使用

    公开(公告)号：WO2012178078A2

    公开(公告)日：2012-12-27

    申请号：PCT/US2012043838

    申请日：2012-06-22

    Applicant: UNIV NORTH DAKOTA ,  NILLES MATTHEW

    Inventor： NILLES MATTHEW

    IPC: A61K39/39 ,  A61K38/16 ,  A61K38/17 ,  A61K39/38 ,  A61P31/00 ,  A61P37/00

    CPC classification number: A61K39/39 ,  A61K39/0291 ,  A61K2039/55544 ,  G01N33/5055

    Abstract: An antigenic composition comprising an antigen and an effective adjuvant, the adjuvant comprising isolated or recombinant YscF, a YscF fragment, trYscF, or homologs thereof. A method of inducing an enhanced immune response comprising administering an antigen and an effective adjuvant comprising isolated or recombinant YscF, a YscF fragment, trYscF, or homologs thereof. An antigenic composition produced by a process comprising providing a host cell with an expression vector containing a nucleotide sequence encoding YscF, a YscF fragment, trYscF, or YscF homolog capable of acting as an adjuvant; expressing the nucleotide sequence in the host cell to produce the protein; and mixing the collected protein with a suitable excipient.

    Abstract translation: 包含抗原和有效佐剂的抗原组合物，所述佐剂包含分离或重组的YscF，YscF片段，trYscF或其同系物。 一种诱导增强的免疫应答的方法，包括施用抗原和有效佐剂，其包含分离或重组YscF，YscF片段，trYscF或其同系物。 通过包括向宿主细胞提供含有能够作为佐剂的编码YscF，YscF片段，trYscF或YscF同源物的核苷酸序列的表达载体产生的抗原组合物; 在宿主细胞中表达核苷酸序列以产生蛋白质; 并将收集的蛋白质与合适的赋形剂混合。

    TREATING AORTIC ANEURYSM BY MODULATING TOLL-LIKE RECEPTORS
    4.
    发明申请
    TREATING AORTIC ANEURYSM BY MODULATING TOLL-LIKE RECEPTORS 审中-公开
    通过调节TOLL样受体来治疗动脉瘤

    公开(公告)号：WO2012068355A3

    公开(公告)日：2012-07-26

    申请号：PCT/US2011061158

    申请日：2011-11-17

    Applicant: TUFTS MEDICAL CT INC ,  GALPER JONAS B

    Inventor： GALPER JONAS B

    IPC: A61K35/74 ,  A61K31/739 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  A61P9/10

    CPC classification number: A61K35/74 ,  A61K31/739 ,  A61K38/08 ,  A61K38/10 ,  A61K38/164 ,  G01N33/505 ,  G01N33/5055 ,  G01N33/6893 ,  G01N2800/329 ,  G01N2800/52

    Abstract: Methods for treating aortic aneurysm, such as abdominal aortic aneurysm (AAA), by either activating TLR2 signaling or suppressing TLR4 signaling and methods for diagnosing aortic aneurysm and assessing aortic aneurysm treatment efficacy in, e.g., a laboratory animal, based on the amount of an immune cell population such as the regulatory T cell population and/or the M1 and M2 macrophage populations. Also disclosed herein are pharmaceutical compositions for use in treating aortic aneurysm, the composition comprising a TLR2 agonist, a TLR4 antagonist, or a combination thereof.

    Abstract translation: 通过激活TLR2信号传导或抑制TLR4信号传导治疗主动脉瘤如腹主动脉瘤（AAA）的方法，以及用于诊断主动脉瘤和评估例如实验动物中的主动脉瘤治疗功效的方法，其基于 免疫细胞群如调节性T细胞群和/或M1和M2巨噬细胞群。 本文还公开了用于治疗主动脉瘤的药物组合物，所述组合物包含TLR2激动剂，TLR4拮抗剂或其组合。

    VERFAHREN ZUR CHARAKTERISIERUNG, INSBESONDERE QUANTIFIZIERUNG, VON DURCH, AUS DEM GEWEBE IN DIE BLUTBAHN REZIRKULIERTEN, BLUTMAKROPHAGEN INTRAZELLULÄR AUS GEWEBE AUFGENOMMENEN MOLEKULAREN MARKERN SOWIE ANALYSEANORDNUNG ZUR DURCHFÜHRUNG DES VERFAHRENS
    5.
    发明申请
    VERFAHREN ZUR CHARAKTERISIERUNG, INSBESONDERE QUANTIFIZIERUNG, VON DURCH, AUS DEM GEWEBE IN DIE BLUTBAHN REZIRKULIERTEN, BLUTMAKROPHAGEN INTRAZELLULÄR AUS GEWEBE AUFGENOMMENEN MOLEKULAREN MARKERN SOWIE ANALYSEANORDNUNG ZUR DURCHFÜHRUNG DES VERFAHRENS 审中-公开
    成分，特别是数量化由从血液中的CAR组织循环，血液巨噬细胞的细胞内从面料的具体产生办法和录制分子标记分析装置

    公开(公告)号：WO2010015633A1

    公开(公告)日：2010-02-11

    申请号：PCT/EP2009/060106

    申请日：2009-08-04

    Applicant: SYNMED RESEARCH GMBH ,  BROZEK, Wolfang

    Inventor： BROZEK, Wolfang

    IPC: G01N33/50

    CPC classification number: G01N33/5055

    Abstract: Die Erfindung betrifft ein Verfahren zur Charakterisierung, insbesondere Quantifizierung, von durch, aus dem Gewebe in die Blutbahn rezirkulierten, Blutmakrophagen intrazellulär aus Gewebe aufgenommenen molekularen Marker(n), wobei folgende Schritte durchgeführt werden: Anwenden eines Mittels auf Vollblut, welches das Verklumpen und/oder Gerinnen von Vollblut hemmt; Durchführen einer Selektion und/oder Anreicherung und/oder Abtrennung von Blutmakrophagen bzw. Blutmakrophagen enthaltenden Leukozytenpopulationen aus dem Vollblut; Durchführung einer Perforation und/oder Lyse der selektierten Blutmakrophagen bzw. Blutmakrophagen enthaltenden Leukozytenpopulationen, gegebenenfalls nach vorheriger Permeabilisierung; Durchführung einer qualitativen und quantitativen Bestimmung von nichtblutmakrophageneigenen Markern, nämlich aus Gewebe stammenden molekularen Markern, nach vorheriger Perforation und/oder Lyse der Blutmakrophagen bzw. Blutmakrophagen enthaltenden Leukozytenpopulationen, sowie eine Anordnung zur Durchführung des Verfahrens.

    Abstract translation: 本发明涉及一种方法，用于表征，在通过特定定量，从组织进入血流循环，血巨噬细胞在细胞内从组织的分子标记（或多个），其特征在于，执行以下步骤采取：将药剂施用到全血，其中聚集和/ 或全血抑制凝血; 执行选择和/或富集和/或含有从全血白细胞群体的血液或血液的巨噬细胞巨噬细胞的分离; 执行含白细胞群，任选现有透后所选择的血液或血液的巨噬细胞巨噬细胞的穿孔和/或裂解; 血液或血液的巨噬细胞巨噬细胞的前穿孔和/或裂解后执行非血巨噬细胞标记物自身，即组织来源的分子标志物的定性和定量测定含白细胞的，以及用于实现该方法的装置。

    CRYSTALLINE CHOLESTROL AND PREVENTION OF ATHEROSCLEROSIS
    6.
    发明申请
    CRYSTALLINE CHOLESTROL AND PREVENTION OF ATHEROSCLEROSIS 审中-公开
    结晶胆固醇和预防甲状腺功能亢进

    公开(公告)号：WO2008131192A3

    公开(公告)日：2010-01-14

    申请号：PCT/US2008060774

    申请日：2008-04-18

    Applicant: UNIV COLUMBIA ,  SCHINDLER CHRISTIAN W ,  SONG LI ,  PERNIS BENVENUTO

    Inventor： SCHINDLER CHRISTIAN W ,  SONG LI ,  PERNIS BENVENUTO

    IPC: G01N33/53 ,  C40B30/00

    CPC classification number: G01N33/92 ,  G01N33/5055 ,  G01N2800/323

    Abstract: The present invention discloses that innate immune responses to crystalline cholesterol plays a critical a role in directing the chronic inflammatory state associated with the development of atherosclerotic lesions. Hence, identifying the sensor system(s) that both detects and directs the inflammatory response to crystalline cholesterol will provide an opportunity to develop novel therapeutic agents for the treatment of atherosclerosis.

    Abstract translation: 本发明公开了对结晶性胆固醇的先天免疫应答在引导与动脉粥样硬化病变发展相关的慢性炎症状态中起关键作用。 因此，鉴定检测并指导对结晶胆固醇的炎症反应的传感器系统将提供开发用于治疗动脉粥样硬化的新型治疗剂的机会。

    METHODS FOR DIAGNOSIS OF CLOSTRIDIUM DIFFCILE AND METHODS AND VECTORS FOR RECOMBINANT TOXIN EXPRESSION
    7.
    发明申请
    METHODS FOR DIAGNOSIS OF CLOSTRIDIUM DIFFCILE AND METHODS AND VECTORS FOR RECOMBINANT TOXIN EXPRESSION 审中-公开
    用于诊断骨质疏松症的方法和用于重组蛋白表达的方法和载体

    公开(公告)号：WO2009139919A2

    公开(公告)日：2009-11-19

    申请号：PCT/US2009003055

    申请日：2009-05-15

    Applicant: UNIV TUFTS ,  FENG HANPING ,  TZIPORI SAUL ,  YANG GUILIN

    Inventor： FENG HANPING ,  TZIPORI SAUL ,  YANG GUILIN

    IPC: G01N33/569

    CPC classification number: G01N33/56911 ,  G01N33/5014 ,  G01N33/5055 ,  G01N2333/33

    Abstract: Cell-based methods for rapid real time assay of a presence of Clostridium difficile toxin and/or cells are provided, using an assay having a toxin-enhancing antibody and a sensitive cell line carrying Fc?R receptors, and kits for this assay. An ultrasensitive cell- based immunocytotoxicity assay for detecting less then 1 pg/ml of C. difficile toxins in clinical samples. The assay is simple, has a turnaround time of approximately 3 hours, and detects less than about 1 pg/ml of toxin A. The presence of C. difficile toxins in the fecal and serum specimens of experimentally infected piglets was detected with this assay. The cellular effects of TcdA were substantially enhanced via an opsonizing antibody through Fc gamma receptor I (Fc?RI)-mediated endocytosis. A TcdA-specific monoclonal antibody, A1H3, was found to significantly enhance the cytotoxicity of TcdA to macrophages and monocytes. The A 1H3 -dependent enhancement of glucosyltransferase activity, cytoskeleton disruption, and TNF-a production induced by TcdA was demonstrated also in RAW 264.7 cells. The interaction of Fc?RI with A1H3 underlay the antibody-dependent enhancement of cellular effects of TcdA. Expression of Fc?RI in CHO cells strikingly enhanced their sensitivity to TcdA complexed with A1H3. Presence of A1H3 facilitated the cell surface recruitment of TcdA, conxributing to the antibody-dependent, Fc?RI -mediated enhancement of TcdA activity. The effect of chlorpromazine and endosomal acidification inhibitors indicated an important role of the endocytic pathway in AlH3-dependent enhancement of TcdA activity. Methods for high level recombinant expression of C. difficile toxins in Bacillus cells, and vectors for expression, strains of Bacillus carrying the vectors are provided.

    Abstract translation: 使用具有毒素增强抗体和携带FcγR受体的敏感细胞系的测定法和用于该测定的试剂盒提供了用于快速实时测定艰难梭菌毒素和/或细胞存在的基于细胞的方法。 用于在临床样品中检测少于1pg / ml艰难梭菌毒素的超敏感的基于细胞的免疫细胞毒性测定。 该测定很简单，具有约3小时的周转时间，并且检测到小于约1pg / ml的毒素A.使用该测定法检测艰难梭菌毒素在实验感染的仔猪的粪便和血清标本中的存在。 通过Fcγ受体I（FcγRI）介导的内吞作用的调理性抗体，TcdA的细胞效应显着增强。 发现TcdA特异性单克隆抗体A1H3显着增强TcdA对巨噬细胞和单核细胞的细胞毒性。 在RAW 264.7细胞中也证明了由TcdA诱导的葡萄糖基转移酶活性，细胞骨架破坏和TNF-α产生的A 1H3依赖性增强。 FcγRI与A1H3的相互作用支持TcdA的细胞效应的抗体依赖性增强。 CHO细胞中FcγRI的表达显着提高了它们对与A1H3复合的TcdA的敏感性。 A1H3的存在促进了TcdA的细胞表面募集，促进了抗体依赖性，FcγRI介导的TcdA活性的增强。 氯丙嗪和内体酸化抑制剂的作用表明，内吞途径在AlH3依赖性增强TcdA活性中起重要作用。 提供了在芽孢杆菌细胞中高水平重组表达艰难梭菌毒素的方法和用于表达载体的载体载体的芽孢杆菌菌株。

Patent Agency Ranking